GLOBUS MEDICAL INC
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Other Information
On August 12, 2025, Daniel T. Scavilla, former President and Chief Executive Officer, terminated a Rule 10b5-1 Trading Plan. Mr. Scavilla’s Rule 10b5-1 Trading Plan, had a term ending upon the earlier of December 31, 2025 or the sale of all shares subject to the plan. At the time of termination, the sale of 80,000 shares of Class A common stock remained authorized under the plan.
On August 25, 2025, Kyle R. Kline, Chief Financial Officer and Senior Vice President, adopted a Rule 10b5-1 Trading Plan. Mr. Kline’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of November 30, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 29,324 stock options pursuant to the terms of the plan. Mr. Kline’s Rule 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
On September 12, 2025, Leslie V. Norwalk, Member of the Board of Directors, adopted a Rule 10b5-1 Trading Plan. Ms. Norwalk’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of September 11, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 8,000 shares of Class A common stock pursuant to the terms of the plan. Ms. Norwalk’s Rule 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act.
Item 6.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.